Medytox said Tuesday that it has received sales approval for Neuramis Deep, a hyaluronic acid filler, in Thailand.

The company expects that the approval, which is the first domestic hyaluronic acid filler approved in Thailand, will create a positive synergy in the with the company’s Medytoxin, its botulinum toxin (BTX) type A product. Medytoxin entered the Thai BTX market in 2008, and currently has the largest market share in the country for its product’s superior product quality since 2013.

Neuramis Deep enhanced the efficiency of the hyaluronic acid crosslinking reaction to increase its persistence while improving its purification process to remove the residues of butanediol diglycidyl ether (BDDE) below the standard levels. Also, the company improved its product quality by using hyaluronic acid approved by both the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) as the product’s raw material.

To enter Thailand successfully, the company has established MedyCeles, a joint venture with Celeste, and has laid out an optimal customized marketing strategy last year.

“The fact that hyaluronic acid filler developed with our technology was classified as a pharmaceutical product in the strictly regulated Thailand market has proved our excellent R&D capability,” a company official said. “We plan to introduce the excellence of Korean filler to Thailand, which is leading the Southeast Asian cosmetic molding market.”

With Neuramis’ entry into the Thai market, the company’s plan to expand Neuramis globally will receive additional momentum, he added.